H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Springworks Therapeutics (NASDAQ:SWTX) on Wednesday, setting a price target of $137, which is approximately 102.27% above the present share price of $67.73.
Burns expects Springworks Therapeutics to post earnings per share (EPS) of -$0.84 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Springworks Therapeutics, with an average price target of $122.
The analysts price targets range from a high of $137 to a low of $107.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$40.9 million. The company's market cap is $3.34 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.1% and a 20.73% success rate.
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.